PERCEIVE-Outreach: A scalable care model to help people with Long COVID manage heart and lung symptoms

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The trial evaluates the PERCEIVE-Outreach program, a three-part approach consisting of screening to identify those most likely to benefit, a remote clinical review of heart and lung health, and a personalized exercise plan delivered through telehealth. It targets adults aged 40 and older with a history of COVID-19 who are currently experiencing fatigue, shortness of breath, or chest pain and have impaired functional capacity. The study uses a disease-management framework to see if this model can reduce symptoms and increase daily activity. Enrollment is located in Australia, with collaboration between University of Tasmania and partner institutes. Primary outcomes focus on functional capacity and patient-reported outcomes relevant to cardiovascular and respiratory symptoms.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Aged forty years or older
* Impaired estimated functional capacity using DASI as proxy (defined by age-normative metabolic equivalent of tasks \[METs\])
* History of COVID-19 (stratified by hospital admission)
* Currently symptomatic with fatigue, dyspnoea or chest pain symptoms
* Medicare eligibility
* Ability and willingness to provide written informed consent to participate in the study. The patient will need to be able to communicate fluently with the investigator. The investigator will need to be satisfied that the patient understands the study by having them explain the study plan back to the investigator.

Exclusion Criteria:

* Unable to provide written informed consent to participate in this study
* Participating in another research trial where randomized treatment would be unacceptable
* Mobility impairment that would impact participants' ability to perform exercise
* History of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)
* Known valvular stenosis or regurgitation of \>moderate severity, history of previous heart failure (baseline New York Heart Association \[NYHA\] \>2)
* Oncologic (or other) life expectancy \<12 months or any other medical condition (including pregnancy) that results in the belief (deemed by the Chief Investigators) that it is not appropriate for the patient to participate in this trial

Where it's running

• Menzies Insititute for Medical Research
  Hobart, Tasmania, Australia Recruiting
• Baker Heart and Diabetes Institute
  Melbourne, Victoria, Australia Not yet recruiting

Study contacts

• Study coordinator: Quan Huynh, PhD
• Email: quan.huynh@utas.edu.au; quan.huynh@baker.edu.au
• Phone: +61 03 8532 1833

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Whole-body Cryotherapy for Fatigue in ME/CFS, Fibromyalgia, Long COVID

  This study tests whether brief, repeated exposure to extreme cold can help reduce fatigue and related symptoms in adults with ME/CFS, fibromyalgia, or Long COVID compared to healthy controls.

  Recruiting Oxford Brookes University · Oxford, Oxon · NCT07874217

• Fatigue Investigation Using Digital Outcomes

  This study tests whether digital monitoring with a smartphone app and wearables can track fatigue in people with MS or long COVID, compared with healthy volunteers.

  Recruiting at 6 sites University of Zurich · Basel, Basel and 5 other locations · NCT07783074

• Biomarker study to understand Long COVID using VIPER

  This study tests biomarkers in people with Long COVID and those who recovered from COVID-19 to see how they can diagnose and track the condition over time.

  Recruiting University of California, San Francisco · San Francisco, California · NCT07770022

• Testing PNMR plus standard care for long COVID

  We’re trying PNMR along with standard care to see if it helps people with long COVID better than standard care alone.

  Recruiting at 4 sites Phase 2 ParagonClinicals Inc. · Brampton, Ontario and 3 other locations · NCT07627815

• Combination therapy for Long COVID symptoms using valacyclovir, celecoxib, and Paxlovid

  This study tests whether a three-drug combination can reduce Long COVID symptoms in adults compared with a placebo.

  Recruiting Phase 2 Icahn School of Medicine at Mount Sinai · New York, New York · NCT07597902

• Right-sided stellate ganglion block for persistent long COVID symptoms

  This trial will test whether a single right-sided stellate ganglion block with bupivacaine can help adults with long COVID who have ongoing breathlessness, fatigue, and cognitive problems.

  Recruiting Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec · Trois-Rivières, Quebec · NCT07374562

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.